DOGWOOD THERAPEUTICS INC 2026年展望:Halneuron推进至2B期开发阶段,最终数据预计于2026年第三季度公布

美股速递
Jan 20

DOGWOOD THERAPEUTICS INC在2026年将继续推进其候选药物Halneuron的临床开发进程,目前该药物已进入关键的2B期临床试验阶段。公司计划稳步推进相关研究工作,最终的2B期临床试验数据预计将在2026年第三季度正式对外公布。这一重要时间节点的设定,标志着Halneuron研发项目取得了实质性进展,也为后续的临床开发路径奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10